About Affigen
Affigen is a company based in Saint Louis (United States) founded in 2016. Affigen has raised $17 million across 1 funding round from investors including Black Beret Life Sciences. Affigen operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Saint Louis, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website affigen.com/en-us
- Social LinkedIn X YouTube
- Total Equity Funding$17M (USD)
in 1 rounds
- Latest Funding Round$17M (USD), Series A
Feb 2017
- Investors
Apps and channels of Affigen
its YouTube channel AffiGEN has 20 subscribers and 11 videos.
Videos from Affigen
The most watched videos on Affigen's YouTube channel, AffiGEN (20 subscribers). Click a video to play it here.
More on AffiGEN.
Funding Insights of Affigen
Affigen has successfully raised a total of $17M through 1 strategic funding round. The most recent funding activity was a Series A round of $17 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 1
- Last Round Series A — $17M
- First Round $17M
(Feb 2017)
- Investors Count 1
All 1 funding rounds of Affigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $17M | Series A | – | Black Beret Life Sciences | – |
1 investors in total: 1 institutional.
Investors in Affigen
Affigen has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Black Beret Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | bbls.net | - |
Investor details for Affigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Affigen
2 dated milestones of Affigen across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Affigen is founded.
- Funding First funding round of $17.0M.
Competitors of Affigen
Affigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Affigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Affigen
The website of Affigen (affigen.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 11.3% vs previous month
Websites whose visitors overlap most with Affigen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| westbioscience.com | 100% | – | #8,837,327 | View details | |
| sydlabs.com | 94% | – | #3,425,883 | View details | |
vazymeglobal.com | vazymeglobal.com | 80% | – | #1,027,905 | – |
Similar companies to Affigen
10 companies that operate in the same segment as Affigen (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Affigen
Affigen was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Affigen is headquartered in Saint Louis, United States. It is registered at Saint Louis, Missouri, United States.
Affigen is a funded company, having raised a total of $17M across 1 funding round to date. The company's 1st funding round was a Series A of $17M, raised on Feb 2017.
Affigen was founded in 2016 and is based in Saint Louis, United States. Therapeutics are being developed by the company to identify and target tumour proteins specific to cell lineages, with lead programs focused on haematological malignancies. These programs remain in the preclinical stage, addressing needs within the biotechnology sector for oncology treatments. Operations center on research and development in this specialized area.
Affigen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Affigen has 1 investor. Key investors include Black Beret Life Sciences.